<DOC>
	<DOCNO>NCT01366482</DOCNO>
	<brief_summary>The DEFINITIVE AR study prospective , multi-center , randomize pilot study evaluate use either TurboHawk™ SilverHawk® plaque excision system follow treatment Cotavance™ drug-eluting balloon catheter versus Cotavance balloon catheter alone patient peripheral arterial disease .</brief_summary>
	<brief_title>Atherectomy Followed Drug Coated Balloon Treat Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Rutherford Clinical Category 24 At least 18 year age Is able willing provide write informed consent prior study specific procedure Has life expectancy le 24 month Is pregnant , childbearing potential take adequate contraceptive measure , nursing Has one contraindication list SilverHawk/ TurboHawk Cotavance IFUs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Peripheral arterial disease ,</keyword>
	<keyword>claudication ,</keyword>
	<keyword>atherectomy ,</keyword>
	<keyword>plaque excision ,</keyword>
	<keyword>drug-coated balloon</keyword>
	<keyword>drug-eluting balloon</keyword>
</DOC>